Brief: Bicara Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business Update
30/03/2026 12:59
March 30 (Reuters) - Bicara Therapeutics Inc BCAX.O: BICARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE BICARA THERAPEUTICS: INITIATED PHASE 3 OF THE FORTIFI-HN01 PIVOTAL TRIAL; INTERIM ANALYSIS EXPECTED MID-2027 BICARA THERAPEUTICS INC - Q4 NET LOSS $37.4 MILLION; FY2025 NET LOSS $138.0 MILLION Source text: ID:nGNX4QXTnG Further company coverage: BCAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicara Therapeutics
See all newsBrief: Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Bicara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027
Brief: Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors